Tickers

1. Composite Trajectory Verdict

All three financial statements carry roughly equal weight for assessing Elanco: the income statement reveals product-cycle traction masked by recurring restructuring and one-time items; the cash flow statement shows the operational cash generation funding deleveraging and investment; and the balance sheet reflects both debt reduction and new liability structures (finance lease, royalty sale) that alter leverage optics.

Composite Trajectory: Mixed

Revenue growth is consistent (annual +6% in 2025, YTD +13% in 2026) and operating cash flow has risen three consecutive years ($271M → $541M → $560M). However, GAAP net income remains volatile (-$1,231M → +$338M → -$232M) due to goodwill impairment, divestiture gain, and escalating restructuring charges ($127M → $150M → $237M). The balance sheet shows core debt declining ($4,321M → $3,762M) but adds a $255M finance lease liability and a $304M royalty-sale liability, while inventories and receivables grow faster than revenue. YTD 2026 improves on net income ($111M vs $78M) and operating cash flow ($290M vs $233M), yet interest expense jumps 32% from imputed interest on the royalty sale.

2. Red Flags

• Restructuring and impairment charges have risen each year: $127M (2023) → $150M (2024) → $237M (2025), with $25–30M more expected in 2026 (10-K 2025-12-31, Statement of Operations; 10-Q 2026-06-30, MD&A)
• Imputed interest on the liability for sale of future revenue added $33M to 2025 interest expense and $29M in YTD 2026, lifting interest expense 32% YoY despite lower average debt balances (10-K 2025-12-31, Note 10; 10-Q 2026-06-30, MD&A)
• Inventories grew 10% to $1,737M in 2025 while revenue grew 6%; accounts receivable jumped 23% QoQ to $1,077M at June 30, 2026 (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet)
• GAAP net income swung from -$1,231M (2023) to +$338M (2024) to -$232M (2025) driven by non-recurring items (goodwill impairment, aqua divestiture gain, restructuring) (10-K 2025-12-31, Statement of Operations)
• New finance lease liability of $255M (corporate headquarters) and sale-of-future-revenue liability of $304M ($315M at June 2026) increase reported leverage without traditional debt proceeds (10-K 2025-12-31, Balance Sheet, Note 7, Note 10; 10-Q 2026-06-30, Balance Sheet)
• Effective tax rate highly volatile: (3.5)% in 2025 vs 30.7% in 2024 vs 7.6% YTD 2025 vs 22.3% YTD 2026, driven by jurisdictional mix and discrete items (10-K 2025-12-31, Statement of Operations; 10-Q 2026-06-30, MD&A)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Revenue rose 6% to $4,715M in 2025 (10-K 2025-12-31, Statement of Operations) and 13% YTD to $2,739M in 2026 (10-Q 2026-06-30, Statement of Operations), driven by volume from new products (Zenrelia, Credelio Quattro, AdTab) and pricing. Gross margin held near 55% annually (55.0% in 2025 vs 54.9% in 2024) and improved to 57.8% YTD 2026 from 57.4% YTD 2025. Marketing, selling and administrative expenses grew 9% to $1,430M in 2025 and 12% YTD to $830M. Asset impairment, restructuring and other special charges escalated to $237M in 2025 (from $150M) and $25M YTD 2026 (from $10M). Net income swung to -$232M in 2025 from +$338M in 2024, but YTD 2026 shows $111M vs $78M a year earlier. Interest expense rose 32% YTD to $116M due to $29M of imputed interest on the royalty sale liability.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Net cash from operating activities increased for the third consecutive year: $271M (2023) → $541M (2024) → $560M (2025) (10-K 2025-12-31, Statement of Cash Flows). YTD 2026 operating cash flow reached $290M vs $233M YTD 2025 (+$57M) (10-Q 2026-06-30, Statement of Cash Flows). Capital expenditures rose to $276M in 2025 (from $147M) and $138M YTD 2026 (vs $176M YTD 2025, net of $76M AHV acquisition payment) (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A). Free cash flow (operating less capex) was $284M in 2025 and $152M YTD 2026. Financing cash outflows reflect debt repayment: $2,669M repaid in 2025 (including Term Loan B 2027 payoff) and $89M YTD 2026 (10-K 2025-12-31, Statement of Cash Flows; 10-Q 2026-06-30, Statement of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Cash and equivalents grew to $545M at December 2025 from $352M at December 2023 (10-K 2025-12-31, Balance Sheet), then dipped to $530M at June 2026 (10-Q 2026-06-30, Balance Sheet). Long-term debt (excluding finance lease) fell to $3,762M from $4,321M (10-K 2025-12-31, Note 7). However, a $255M finance lease liability (headquarters) and a $304M liability for sale of future revenue (growing to $315M at June 2026) were added (10-K 2025-12-31, Balance Sheet, Notes 7, 10; 10-Q 2026-06-30, Balance Sheet). Total liabilities rose to $6,811M from $6,518M. Equity increased to $6,547M from $6,096M, driven by $630M of other comprehensive income (primarily foreign currency translation gains) in 2025 (10-K 2025-12-31, Statement of Comprehensive Income). Inventories rose 10% to $1,737M and accounts receivable 8% to $873M in 2025; receivables surged 23% to $1,077M at June 2026.

6. Data Gaps

• Stand-alone quarterly income statements and cash flows for Q1 2026, Q4 2025, Q3 2025, and Q1 2025 (only YTD and Q2 2026 figures provided in detail)
• Full 2026 Q1 and Q2 balance sheets with comparative prior-year quarters (only June 30, 2026 vs December 31, 2025 shown)
• Segment-level profitability or contribution margins (company reports single segment)
• Adjusted EBITDA or non-GAAP earnings metrics referenced in MD&A but not reconciled in detail
• Detailed debt maturity schedule beyond the five-year summary in the 10-K (only 2026–2031+ buckets provided)
• Quarterly cash flow statements for Q1 2026 and Q2 2026 individually (only YTD aggregated)